Boston Scientific Corp (BSX)vsElutia Inc. (ELUT)
BSX
Boston Scientific Corp
$44.61
-2.58%
HEALTHCARE · Cap: $60.84B
ELUT
Elutia Inc.
$0.75
-1.15%
HEALTHCARE · Cap: $36.36M
Smart Verdict
WallStSmart Research — data-driven comparison
Boston Scientific Corp generates 173516% more annual revenue ($21.07B vs $12.14M). ELUT leads profitability with a 426.9% profit margin vs 16.6%. BSX earns a higher WallStSmart Score of 62/100 (C+).
BSX
Buy62
out of 100
Grade: C+
ELUT
Avoid35
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-7.2%
Fair Value
$39.17
Current Price
$44.60
$5.43 premium
Margin of Safety
-0.0%
Fair Value
$0.90
Current Price
$0.75
$0.15 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Large-cap with strong market position
Growing faster than its price suggests
Attractively priced relative to earnings
Reasonable price relative to book value
Strong operational efficiency at 20.2%
Generating 1.3B in free cash flow
Every $100 of equity generates 221 in profit
Keeps 427 of every $100 in revenue as profit
Reasonable price relative to book value
Areas to Watch
1.4% revenue growth
Distress zone — elevated risk
Earnings declined 21.5%
0.0% earnings growth
Smaller company, higher risk/reward
Revenue declined 11.6%
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : BSX
The strongest argument for BSX centers on Market Cap, PEG Ratio, P/E Ratio. Profitability is solid with margins at 16.6% and operating margin at 20.2%. PEG of 0.63 suggests the stock is reasonably priced for its growth.
Bull Case : ELUT
The strongest argument for ELUT centers on Return on Equity, Profit Margin, Price/Book. Profitability is solid with margins at 426.9% and operating margin at -243.1%.
Bear Case : BSX
The primary concerns for BSX are Revenue Growth, Altman Z-Score, EPS Growth.
Bear Case : ELUT
The primary concerns for ELUT are EPS Growth, Market Cap, Revenue Growth.
Key Dynamics to Monitor
BSX profiles as a value stock while ELUT is a declining play — different risk/reward profiles.
ELUT carries more volatility with a beta of 0.92 — expect wider price swings.
BSX is growing revenue faster at 1.4% — sustainability is the question.
BSX generates stronger free cash flow (1.3B), providing more financial flexibility.
Bottom Line
BSX scores higher overall (62/100 vs 35/100), backed by strong 16.6% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Boston Scientific Corp
HEALTHCARE · MEDICAL DEVICES · USA
Boston Scientific Corporation, doing business as Boston Scientific, is a manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.
Elutia Inc.
HEALTHCARE · MEDICAL DEVICES · USA
Elutia Inc., a commercial-stage company, engages in developing and commercializing drug-eluting biomatrix technology to enhance surgical outcomes. The company is headquartered in Silver Spring, Maryland.
Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?